Cargando…
Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance
BACKGROUND: Retroperitoneal liposarcoma (RLPS) is a rare tumor with high recurrence rate. Ribonucleotide reductase small subunit M2 (RRM2) protein is essential for DNA synthesis and replication. Our previous study has demonstrated that RRM2 downregulation inhibited the proliferation of RLPS cells, b...
Autores principales: | Zhang, Sha, Yan, Liang, Cui, Can, Wang, Zhen, Wu, Jianhui, Lv, Ang, Zhao, Min, Dong, Bin, Zhang, Wenlong, Guan, Xiaoya, Tian, Xiuyun, Hao, Chunyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342604/ https://www.ncbi.nlm.nih.gov/pubmed/32753891 http://dx.doi.org/10.2147/OTT.S246613 |
Ejemplares similares
-
Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence
por: Zhang, Sha, et al.
Publicado: (2020) -
Comprehensive immune characterization and T‐cell receptor repertoire heterogeneity of retroperitoneal liposarcoma
por: Yan, Liang, et al.
Publicado: (2019) -
Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study
por: Xu, Chang, et al.
Publicado: (2022) -
Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma
por: Xu, Chang, et al.
Publicado: (2022) -
RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT/mTOR Signaling Pathway
por: Jiao, Yuheng, et al.
Publicado: (2022)